Zamtocabtagene Autoleucel Produces High ORR in Relapsed/Refractory DLBCL
Zamtocabtagene autoleucel produced responses in patients with relapsed/refractory diffuse large B-cell lymphoma in a phase 2 trial.
Zamtocabtagene autoleucel produced responses in patients with relapsed/refractory diffuse large B-cell lymphoma in a phase 2 trial.
A prognostic index called “Severe4” can predict outcomes of CAR T-cell therapy in patients with relapsed/refractory DLBCL, a study suggests.
A study evaluating the use of chronotherapy for hematologic cancers identifies how the approach can improve outcomes for some patients.
Progression-free, overall survival significantly lower for female patients receiving chemo mostly in morning.
Researchers sought to determine whether the use of second-line CAR-T therapy could be cost effective in DLBCL.
Results of a phase 1/2 trial suggest the combination of atezolizumab and R-CHOP does not warrant further study in DLBCL, according to researchers.
Long-acting G-CSF can reduce the risk of hospitalization related to febrile neutropenia in patients with DLBCL treated with R-CHOP.
The aim of this trial was to evaluate the efficacy and safety of orelabrutinib with RCHOP in patients with extranodal non-GCB DLBCL.
Researchers sought to identify genomic features in patients with large B-cell lymphoma that are linked with anti-CD19 CAR-T therapy.
Researchers sought to determine patterns in coagulation parameters linked to cytokine-release syndrome in patients receiving CAR-T therapy.